Immunic Appoints Chief Data Officer
Analysis based on 8 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The appointment of a Chief Data and Digital Officer signals Immunic's preparation for commercial readiness, which may be viewed positively by investors as the company approaches key clinical milestones. The move is unlikely to have a significant immediate impact on the stock price, but it underscores the company's commitment to building infrastructure for potential NDA submission and commercialization.
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company, announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective September 1, 2026. Davé will report directly to CEO Ockelbo-Lundgren and join the executive leadership team. In this newly created role, he will lead the company's enterprise-wide data, analytics, AI, and digital strategy, supporting the preparation of the data package for a potential New Drug Application (NDA) for vidofludimus calcium (IMU-838) in multiple sclerosis. The appointment comes as Immunic prepares for top-line data from its Phase 3 ENSURE trials by year-end and plans for a confirmatory Phase 3 program in progressive MS. Davé brings over 25 years of experience, having previously served at Avidity Biosciences, Edwards Lifesciences, and Medtronic. As part of the appointment, Immunic granted Davé an option to purchase 120,000 shares of common stock under its 2026 Inducement Equity Compensation Plan, vesting over four years.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard